Regeneron Pharma (REGN) Price Target Raised to $455 at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Regeneron Pharma (REGN) Price Target Raised to $410 at RBC
November 4, 2014 3:28 PM ESTRBC Capital maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $410.00 (from $373.00). Comments follow Q3 results. Analyst Adnan Butt said he was a buyer of pullbacks.
"While ramp from DME did not materialize, the... More
Regeneron (REGN) Misses Q3 EPS by 5c
November 4, 2014 6:31 AM ESTRegeneron (NASDAQ: REGN) reported Q3 EPS of $2.52, $0.05 worse than the analyst estimate of $2.57. Revenue for the quarter came in at $726 million versus the consensus estimate of $733.04 million.
Pipeline Progress
Regeneron has sixteen fully human monoclonal antibodies generated using the Company's VelocImmune® technology in clinical development, including six in collaboration with Sanofi. Highlights from the late-stage antibody pipeline include:
Alirocumab, the Company's antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) to lower LDL-cholesterol (LDL-C), is currently being evaluated in the global Phase 3 ODYSSEY program. In July 2014, the Company and Sanofi reported... More
